Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy (AOITC)

17 september 2026 uppdaterad av: AO Innovation Translation Center

Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy: A Multi-center Retrospective Cohort Study

Osteoradionecrosis (ORN) of the jaw is a serious complication that can occur after radiation therapy for head and neck cancers, including oral cavity cancer (OCC). ORN happens when jawbone tissue dies and fails to heal, often triggered by dental issues like tooth extractions or poorly fitting dentures. Symptoms can include exposed bone, pain, difficulty opening the mouth, trouble swallowing, and even jaw fractures-leading to major physical and emotional challenges.

The likelihood of ORN varies widely, from less than 1% to over 50% in head and neck cancer patients. For OCC specifically, studies report rates from 4% up to 25%. Treatment depends on how much bone is affected and can range from medication to major surgery.

Risk factors include radiation dose, tumor location, oral health, dental extractions, lifestyle habits (like alcohol use), and other health conditions. Poor oral hygiene, high radiation doses, and alcohol use are among the most common risks. However, current data on OCC patients is limited and often not broadly applicable.

This study will retrospectively examine what increases the risk of ORN in OCC patients who received radiation therapy before or after surgery. Using data from multiple international centers, it aims to identify patterns and provide globally relevant insights. The results will help guide prevention strategies and create evidence-based guidelines to reduce ORN and improve long-term outcomes for these patients.

Studieöversikt

Status

Har inte rekryterat ännu

Studietyp

Observationell

Inskrivning (Beräknad)

1000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients will be selected from the primary care center where the patients received their initial treatment and followed up for at least 24months

Beskrivning

Inclusion Criteria:

  • Adults (≥18 years) diagnosed with OCC and treated with radiotherapy with curative intent (preoperative or/and postoperative, not palliative; definitive RT)
  • Patients who completed the full prescribed radiotherapy course; patients remain eligible if radiotherapy was discontinued due to suspected and subsequently confirmed ORN
  • Available, complete medical records including RT details, oral status, comorbidities, dental procedure details (as applicable), and lifestyle factors (as applicable)
  • Documented informed consent from the treated patient, where applicable, permitting the use of their medical records for research purposes, in accordance with the requirements of the Institutional Review Board (IRB) or Ethics Committee (EC).
  • Availability of at least 24 months of follow-up data after completion of radiotherapy, or follow-up until the occurrence of ORN, death, or loss to follow-up, whichever occurs first.
  • Completion of the radiotherapy course on or before 31 December 2024.

Exclusion Criteria:

  • Patients with non-oral cavity primary cancers (eg, oropharynx, larynx)
  • Patients treated only with surgery or conservatively, without any form of RT
  • Incomplete or missing medical records
  • Record of use of antiresorptive (eg, bisphosphonate, denosumab) and antiangiogenic drugs
  • Patients with jaw necrosis attributable to non-radiation-related causes, such as medication-related osteonecrosis of the jaw (MRONJ), trauma, or odontogenic infections
  • Patients with known metastatic bone disease in the jaw
  • Patients who discontinued radiotherapy for reasons unrelated to ORN suspicion or confirmation (eg, death, dropout, treatment intolerance, or other non-ORN related causes)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: RETROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Cases (ORN group)

Developed clinically and radiographically or histologically confirmed osteoradionecrosis (ORN) of the jaw following radiotherapy.

Control (non-ORN group)

No clinical, radiological, or histological diagnosis of ORN during the follow-up period.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Development of osteoradionecrosis (ORN) of the jaw
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

The primary outcome is the development occurrence (yes/no) of ORN after completion of pre- and/or postoperative RT. The objective is to identify and evaluate patient-, tumor-, treatment-, and region-related risk factors associated with the development of ORN across multiple geographic regions.

Scoring Scale:

The primary endpoint will be treated as a binary variable:

0 = No ORN

1 = Development of ORN Time to ORN onset (interval between completion of RT and clinical diagnosis of ORN) will also be recorded for time-to-event analyses.

After completion of pre-and/or postoperative radiotherapy up to 24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of ORN Across Geographic Regions
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence rates across geographical regions, namely between the Eastern and Western world, and High-Income Countries versus Low and Middle-Income Countries.

After completion of pre-and/or postoperative radiotherapy up to 24 months
Severity of ORN by Tumor Characteristic
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To evaluate the variability in the severity of osteoradionecrosis (ORN) based on primary tumor site (eg, tongue, floor of mouth, oral tongue, buccal mucosa, gingiva), histological tumor type (eg, adenoid cystic carcinoma, squamous cell carcinoma), and tumor characteristics including size, clinical stage (T1-T4), overall stage (III-IVA), and nodal status (N0, N1-2B, N2C, N3

After completion of pre-and/or postoperative radiotherapy up to 24 months
Association between radiotherapy dose and ORN severity
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To investigate the association between radiotherapy dose parameters (total dose and duration) and the severity grade of ORN among patients who develop ORN. Is there a correlation between increased radiation dose and duration and the severity of the condition?

After completion of pre-and/or postoperative radiotherapy up to 24 months
Incidence and severity comparison of preop vs. postop RT
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence and severity of ORN in patients undergoing preoperative versus postoperative radiotherapy

After completion of pre-and/or postoperative radiotherapy up to 24 months
Incidence comparison across RT modalities
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To compare the incidence ORN across different radiation modalities, including intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), and conventional three-dimensional conformal radiotherapy (3D-CRT)

After completion of pre-and/or postoperative radiotherapy up to 24 months
To determine whether the mandible is more susceptible to ORN than the maxilla, or vice versa.
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To determine whether the mandible is more susceptible to ORN than the maxilla, or vice versa.

After completion of pre-and/or postoperative radiotherapy up to 24 months
Complication evaluation with pre- or postop RT
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To evaluate potential complications associated with preoperative and postoperative radiotherapy

After completion of pre-and/or postoperative radiotherapy up to 24 months
To analyze the influence of pre-radiotherapy dental extractions and oral hygiene status on the risk of developing ORN
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To analyze the influence of pre-radiotherapy dental extractions and oral hygiene status on the risk of developing ORN

After completion of pre-and/or postoperative radiotherapy up to 24 months
To examine the variability in ORN incidence and severity between patients who undergo dental extractions before versus after the completion of RT
Tidsram: After completion of pre-and/or postoperative radiotherapy up to 24 months

To examine the variability in ORN incidence and severity between patients who undergo dental extractions before versus after the completion of RT

After completion of pre-and/or postoperative radiotherapy up to 24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Khalid Abdel-Galil, MD, Hamad Medical Corporation PO Box 3050 Doha, Qatar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 mars 2027

Primärt slutförande (Beräknad)

15 juni 2029

Avslutad studie (Beräknad)

15 juli 2029

Studieregistreringsdatum

Först inskickad

27 juli 2026

Först inskickad som uppfyllde QC-kriterierna

17 september 2026

Första postat (Faktisk)

23 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 september 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera